推进药物输送:用于控制释放系统的MOF-聚氨复合材料的设计和应用
Chang Yan1, Shuhui Hu1, Qiang Fei1
1School of Food Science and Engineering, Guiyang University, Guiyang, Guizhou 550005, China.
ACS omega
|October 6, 2025
概括
金属有机框架聚氨 (MOF-PU) 复合材料提供了增强的药物输送. 这些先进的材料结合了MOF和聚氨的特性,提高了药物负载,稳定性和治疗效率,克服了个体材料的局限性.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 控制释放药物系统对于有效治疗至关重要,需要精确调节药物释放速度和持续时间.
- 纳米材料,特别是金属有机框架 (MOF),由于其独特的特性,显示出作为药物载体的希望,但面临稳定性挑战.
- 聚氨 (PU) 是一种可生物降解的药物载体,但它可能会遭受爆发释放和真菌问题.
研究的目的:
- 审查MOF-PU复合材料作为药物载体的定义,制备,优势和应用.
- 突出将MOF和PU结合用于先进药物递送系统的协同效益.
- 为未来的MOF-PU复合物药物输送研究提供全面的参考.
主要方法:
- 文献综述侧重于用于药物输送的MOF-PU复合材料.
- 分析MOF特性,PU特性及其复合性行为.
- 探索MOF-PU复合材料的制备方法和应用领域.
主要成果:
- 与单个组件相比,MOF-PU复合材料提高了药物载荷能力和溶解性.
- 这些复合材料提供了更好的热稳定性,并减轻与药物输送相关的不良反应.
- 协同作用的组合克服了诸如爆破释放和材料降解等局限性.
结论:
- MOF-PU复合材料代表了药物输送系统的重大进步.
- 它们的量身定制特性使得它们在受控和有针对性的药物释放方面非常有效.
- 对MOF-PU复合材料的进一步研究为制药创新提供了巨大的潜力.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
196
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
196
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
149
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
149
01:16Drug Delivery: Overview
723
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
723
01:10In Vitro Drug Release Testing: Overview, Development and Validation
305
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
305